2023-11-28 08:00
Continued sales growth and several commercial agreements signed! Significant events during the second quarter Significant events after the end of the period Webcast:When: 28/11 2023 kl. 15.00 CETWhere: register via lyyti: https://www.lyyti.fi/reg/Biovica_Q2_Earnings_call_2023__Live_Event_2257Broadcast...
2023-11-24 12:30
Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET. Anders Rylander, CEO, Warren Cresswell, President of...
2023-11-23 14:20
The extra general meeting of Biovica International AB (the "Company") was held today on 23 November 2023 and the following resolution was passed by the meeting. Amendments of the articles of association The extra general meeting resolved, in...
2023-11-21 10:00
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments...
2023-11-13 08:00
Today, Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay. “Axlab is a top-5 brand in cancer screening and diagnostics...
2023-10-23 08:01
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Thursday 23 November 2023, at 14:00 CET at Baker McKenzie Advokatbyrå's offices on Vasagatan...
2023-10-23 08:00
INSIDE INFORMATION: Stockholm, Sweden, October 23, 2023 – The Board of Directors of Biovica International AB (publ) (“Biovica” or the “Company”) (Nasdaq First North Premier Growth Market: BIOVIC B) has resolved to conduct...
2023-10-16 08:30
Biovica today announces that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Diego, California. CAP accreditation is awarded...
2023-10-12 08:45
Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida. This center in Florida is part of a large and well renowned organization...
2023-09-28 10:30
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024. The gap-fill process is an established...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects